A53T Alpha-Synuclein Transgenic Mouse Model of Parkinson's Disease

A53T Alpha-Synuclein Transgenic Mouse Model of Parkinson's Disease

Overview

The A53T alpha-synuclein transgenic mouse model is a genetic model of Parkinson's disease that expresses the human [alpha-synuclein](/proteins/alpha-synuclein) gene with the A53T mutation under the prion protein promoter. This model recapitulates key features of PD including progressive neurodegeneration and protein aggregation[@masliah2011].

Genetic Background

The A53T mutation was first identified in the SNCA gene in the Contursi kindred family, a large kindred with autosomal dominant PD. This mutation results in:

• Alanine → Threonine substitution at position 53
• Enhanced aggregation propensity
• Earlier onset of pathology

Model Characteristics

in CNS"]
B --> C["Protein Misfolding"]
C --> D["Oligomer Formation"]
D --> E["Protofibril Accumulation"]
E --> F["Fibril Formation"]
F --> G["Lewy Body-like Inclusions"]
G --> H["Neuronal Dysfunction"]
H --> I["Neurodegeneration"]
I --> J["Motor Phenotype"]
I --> K["Non-Motor Phenotype"]

Promoter and Expression

| Feature | Details |
|---------|---------|
| Promoter | Mouse prion protein (MoPrP) |
| Expression | Neuronal, throughout CNS |
| Expression level | 2-4x endogenous mouse α-syn |
| Isoforms | Full-length human A53T α-syn |

Key Phenotypes

Motor Symptoms

...

A53T Alpha-Synuclein Transgenic Mouse Model of Parkinson's Disease

Overview

The A53T alpha-synuclein transgenic mouse model is a genetic model of Parkinson's disease that expresses the human [alpha-synuclein](/proteins/alpha-synuclein) gene with the A53T mutation under the prion protein promoter. This model recapitulates key features of PD including progressive neurodegeneration and protein aggregation[@masliah2011].

Genetic Background

The A53T mutation was first identified in the SNCA gene in the Contursi kindred family, a large kindred with autosomal dominant PD. This mutation results in:

• Alanine → Threonine substitution at position 53
• Enhanced aggregation propensity
• Earlier onset of pathology

Model Characteristics

in CNS"]
B --> C["Protein Misfolding"]
C --> D["Oligomer Formation"]
D --> E["Protofibril Accumulation"]
E --> F["Fibril Formation"]
F --> G["Lewy Body-like Inclusions"]
G --> H["Neuronal Dysfunction"]
H --> I["Neurodegeneration"]
I --> J["Motor Phenotype"]
I --> K["Non-Motor Phenotype"]

Promoter and Expression

| Feature | Details |
|---------|---------|
| Promoter | Mouse prion protein (MoPrP) |
| Expression | Neuronal, throughout CNS |
| Expression level | 2-4x endogenous mouse α-syn |
| Isoforms | Full-length human A53T α-syn |

Key Phenotypes

Motor Symptoms

• Reduced locomotion: Decreased exploratory behavior
• Impaired coordination: Deficits on rotarod and beam walking
• Postural instability: Impaired balance
• Muscle weakness: Reduced grip strength

Non-Motor Symptoms

• Sleep disorders: Altered sleep architecture
• Olfactory dysfunction: Early smell identification deficits
• Cognitive impairment: Working memory deficits
• Anxiety-like behavior: Changes in elevated plus maze

Neuropathology

• α-Synuclein inclusions: Lewy body-like structures throughout brain
• Neuronal loss: Progressive loss of dopaminergic neurons in SNc
• Gliosis: Reactive astrocytosis and microgliosis
• Neuroinflammation: Elevated inflammatory markers

Disease Progression

| Age | Pathology | Behavior |
|-----|-----------|----------|
| 2-4 months | Minimal | Normal |
| 4-8 months | Early aggregation | Subtle deficits |
| 8-12 months | Moderate pathology | Clear motor impairment |
| >12 months | Severe neurodegeneration | Marked phenotype |

Advantages and Limitations

Advantages

| Advantage | Description |
|-----------|-------------|
| Genetic relevance | Models familial PD mutation |
| Protein aggregation | Recapitulates Lewy body pathology |
| Progressive model | Age-dependent degeneration |
| Multi-system involvement | Non-motor symptoms present |

Limitations

| Limitation | Description |
|------------|-------------|
| Overexpression | Not physiological levels |
| Promoter choice | Prion promoter not neuron-specific |
| Species difference | Mouse vs human protein dynamics |
| No sporadic trigger | Pure genetic model |

Research Applications

Therapeutic Testing

Used to evaluate:

• Anti-aggregation compounds
• Gene therapy approaches
• Immunotherapy (α-syn antibodies)
• Small molecule inhibitors

Mechanism Studies

Investigation of:

• Aggregation pathways
• Propagation mechanisms
• Neuroinflammation role
• Autophagy/lysosomal dysfunction

Biomarker Studies

• CSF α-synuclein species
• Blood biomarkers
• Imaging markers

Comparison with Other PD Models

| Feature | MPTP | 6-OHDA | A53T |
|---------|------|--------|------|
| Type | Toxin | Toxin | Genetic |
| Onset | Days | Days | Months |
| Aggregation | No | No | Yes |
| Progressive | No | No | Yes |
| Cost | Low | Medium | High |

References

[Masliah et al., Neurodegeneration in A53T mice (2011)](https://pubmed.ncbi.nlm.nih.gov/21303776/)

[Chesselet et al., Regulation of DAT by α-syn (2008)](https://pubmed.ncbi.nlm.nih.gov/18550702/)

Cross-Links

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alpha-Synuclein](/proteins/alpha-synuclein)
• [MPTP Mouse Model](/models/mptp-mouse-model-parkinsons)
• [6-OHDA Rat Model](/models/6-ohda-rat-model-parkinsons)
• [Alpha-Synuclein Aggregation](/mechanisms/alpha-synuclein-aggregation-parkinsons)